Literature DB >> 34295715

Coronavirus disease and the cardiovascular system: a narrative review of the mechanisms of injury and management implications.

Maria Vega Brizneda1, Agam Bansal2, Vardhmaan Jain2, Samir Kapadia1, Lars G Svensson3, Venu Menon1, Paul Cremer1, Grant Reed1, Penelope Rampersad1, Richard Grimm1, Brian P Griffin1, Bo Xu1.   

Abstract

Coronavirus disease (COVID-19), first identified in Wuhan, China, in December 2019, is now a pandemic, having already spread to 188 countries, with more than 28,280,000 infections worldwide. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the responsible infectious agent, and similar to other human coronaviruses, uses membrane-bound angiotensin-converting enzyme 2 (membrane-bound ACE2) for entry into the host cells. COVID-19 has important cardiovascular implications, especially for patients with pre-existing cardiovascular co-morbidities, potentially mediated through several mechanisms, including direct myocardial injury, worsening of those pre-existing cardiovascular co-morbidities, and adverse cardiovascular effects of potential therapies for COVID-19. The disease is causing a significant burden on health systems worldwide. Elective surgeries and procedures were postponed for a considerable period of time, and many patients with known cardiovascular disease (CVD) risk factors presented late to hospitals, for fear of contracting COVID-19, with serious adverse consequences. Significant negative impact on a population level is highlighted by prolonged isolation, decreased exercise and physical activity, and higher levels of depression and anxiety, all predisposing to elevated cardiovascular risk. This article provides a timely overview of COVID-19 and its impact on the cardiovascular system, focusing on the pathogenesis, potential adverse cardiovascular events, the potential treatment options, protection for health care providers and patients, and what the cardiovascular community could do to mitigate the impact of COVID-19. 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  COVID-19; Coronavirus disease; cardiovascular disease (CVD); cardiovascular system; membrane-bound ACE2

Year:  2021        PMID: 34295715      PMCID: PMC8261751          DOI: 10.21037/cdt-20-779

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  68 in total

1.  Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation.

Authors:  Graeme MacLaren; Dale Fisher; Daniel Brodie
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

2.  COVID-19 and Kawasaki Disease: Novel Virus and Novel Case.

Authors:  Veena G Jones; Marcos Mills; Dominique Suarez; Catherine A Hogan; Debra Yeh; J Bradley Segal; Elizabeth L Nguyen; Gabrielle R Barsh; Shiraz Maskatia; Roshni Mathew
Journal:  Hosp Pediatr       Date:  2020-04-07

Review 3.  T cell-mediated immune response to respiratory coronaviruses.

Authors:  Rudragouda Channappanavar; Jincun Zhao; Stanley Perlman
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

4.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.

Authors:  Wei Tang; Zhujun Cao; Mingfeng Han; Zhengyan Wang; Junwen Chen; Wenjin Sun; Yaojie Wu; Wei Xiao; Shengyong Liu; Erzhen Chen; Wei Chen; Xiongbiao Wang; Jiuyong Yang; Jun Lin; Qingxia Zhao; Youqin Yan; Zhibin Xie; Dan Li; Yaofeng Yang; Leshan Liu; Jieming Qu; Guang Ning; Guochao Shi; Qing Xie
Journal:  BMJ       Date:  2020-05-14

5.  Protecting Chinese healthcare workers while combating the 2019 novel coronavirus.

Authors:  Pengcheng Zhou; Zebing Huang; Yinzong Xiao; Xun Huang; Xue-Gong Fan
Journal:  Infect Control Hosp Epidemiol       Date:  2020-06       Impact factor: 3.254

6.  Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus.

Authors:  Tariq Alhogbani
Journal:  Ann Saudi Med       Date:  2016 Jan-Feb       Impact factor: 1.526

7.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

8.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.

Authors:  Keiji Kuba; Yumiko Imai; Shuan Rao; Hong Gao; Feng Guo; Bin Guan; Yi Huan; Peng Yang; Yanli Zhang; Wei Deng; Linlin Bao; Binlin Zhang; Guang Liu; Zhong Wang; Mark Chappell; Yanxin Liu; Dexian Zheng; Andreas Leibbrandt; Teiji Wada; Arthur S Slutsky; Depei Liu; Chuan Qin; Chengyu Jiang; Josef M Penninger
Journal:  Nat Med       Date:  2005-07-10       Impact factor: 53.440

9.  Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2.

Authors:  Yu Zhao; Zixian Zhao; Yujia Wang; Yueqing Zhou; Yu Ma; Wei Zuo
Journal:  Am J Respir Crit Care Med       Date:  2020-09-01       Impact factor: 21.405

10.  Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome.

Authors:  Nicholas S Hendren; Mark H Drazner; Biykem Bozkurt; Leslie T Cooper
Journal:  Circulation       Date:  2020-04-16       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.